BPC-157 is a gastric pentadecapeptide that acts via VEGFR2 and upregulates growth factor expression; TB-500 is a synthetic fragment of thymosin beta-4 that promotes actin polymerisation and cellular migration.
Research reference only — all information on this page summarises peer-reviewed scientific literature and does not constitute medical advice. View full compound profiles: BPC-157 · TB-500
Mechanism Comparison
BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide derived from a region of human gastric juice protein. It promotes angiogenesis through VEGFR2 activation and upregulates growth factors including EGF and FGF. TB-500 corresponds to the actin-sequestering domain of thymosin beta-4 (Tβ4), enabling G-actin binding and promoting cell motility, migration, and tissue remodelling. The two compounds operate through distinct molecular targets and are often studied in combination protocols because their repair mechanisms are considered complementary rather than redundant.
Side-by-Side Attributes
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Source | Synthetic — derived from human gastric juice protein BPC | Synthetic — Tβ4 fragment (actin-binding domain, residues 17–23) |
| Molecular weight | ~1,419 Da (15 amino acids) | ~2,019 Da (17 amino acids) |
| Primary mechanism | VEGFR2 agonism; growth factor (EGF/FGF) upregulation | Actin sequestration (G-actin binding); cell migration promotion |
| Routes in published research | IP, SC, IM, oral (in rodent models) | SC, IM |
| Half-life (approx.) | ~2–4 hours (estimated, rodent models) | ~2–3 hours (estimated) |
| Tissue focus in published research | GI tract, tendon, muscle, CNS, cardiovascular | Muscle, tendon, cardiac tissue, skin wound healing |
| GI research evidence | Extensive (gastric ulcer, IBD, gut permeability models) | Limited direct GI data |
| Cardiac tissue research | Studied in cardiac injury models | Studied in myocardial infarction models (Tβ4 full-length) |
| Regulatory status (US) | Investigational; 503A Cat 2 (restricted) | Investigational; 503A Cat 2 (restricted) |
Key Research Points
- 1BPC-157 has a larger published preclinical literature specifically on GI tract repair; it was originally identified as a cytoprotective factor in gastric juice and has been extensively studied in rodent ulcer and IBD models.
- 2TB-500's actin-sequestering mechanism is distinct — it binds monomeric G-actin, lowering the effective concentration available for F-actin polymerisation and enabling the cellular remodelling that drives tissue repair and angiogenesis.
- 3The two compounds are frequently co-administered in published rodent research because their mechanisms address different phases of the tissue repair cascade: BPC-157 drives angiogenesis and growth factor expression; TB-500 drives cellular migration into the repair zone.
- 4Neither compound has completed Phase 3 clinical trials in humans as of 2026; most published efficacy data comes from rodent models (IP or SC administration) — direct extrapolation to human pharmacokinetics is not established.
- 5Both compounds are classified as 503A Category 2 by the FDA PCAC, meaning they are restricted from 503A compounding pharmacy preparations in the US as of mid-2026.
Frequently Asked Questions
What is the mechanistic difference between BPC-157 and TB-500?
BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic peptide derived from a gastric juice protein that acts primarily through VEGFR2 activation and upregulation of growth factors (EGF, FGF), driving angiogenesis and fibroblast recruitment. TB-500 is a synthetic fragment of thymosin beta-4 corresponding to the actin-sequestering domain; it binds monomeric G-actin, lowering F-actin polymerisation and promoting cellular migration and tissue remodelling. The two mechanisms are complementary: BPC-157 primarily drives the vascular and growth factor response, while TB-500 drives cellular migration into the repair zone.
Which compound has more published preclinical research — BPC-157 or TB-500?
BPC-157 has a substantially larger published preclinical literature. Research dating to the 1990s by Sikiric et al. has produced extensive rodent data across GI, musculoskeletal, CNS, and cardiovascular injury models. TB-500 research is more limited in published form — much of the thymosin beta-4 literature focuses on the full-length Tβ4 protein rather than the synthetic TB-500 fragment specifically. Researchers should note this distinction when interpreting TB-500 studies that cite full-length Tβ4 preclinical data.
Are BPC-157 and TB-500 often used together in research protocols?
Yes — combination protocols appear in the published literature and are common in preclinical research precisely because the two compounds address different aspects of tissue repair. BPC-157 provides angiogenic and growth-factor drive via VEGFR2; TB-500 provides cellular migration support via actin dynamics. Their non-overlapping mechanisms make combination use rational for studies aiming to model comprehensive tissue repair rather than isolating a single pathway. However, researchers should note that pharmacokinetic interaction data for the combination is limited.
Deep Dive
For extended mechanism analysis, trial data, and regulatory context, see the full research article:
TB-500 vs BPC-157: Tissue Repair Peptide Research Comparison →Full compound profile
BPC-157
Full compound profile
TB-500